Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) is expected to post its quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect Cellectar Biosciences to post earnings of ($0.38) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
Cellectar Biosciences Trading Up 12.0 %
Shares of CLRB opened at $0.38 on Wednesday. The firm has a market capitalization of $17.38 million, a P/E ratio of -0.22 and a beta of 0.96. The stock’s fifty day simple moving average is $0.29 and its 200 day simple moving average is $1.13. Cellectar Biosciences has a twelve month low of $0.22 and a twelve month high of $4.17.
Hedge Funds Weigh In On Cellectar Biosciences
A hedge fund recently raised its stake in Cellectar Biosciences stock. Bank of America Corp DE raised its stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) by 25.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 206,783 shares of the biopharmaceutical company’s stock after acquiring an additional 41,704 shares during the period. Bank of America Corp DE owned 0.45% of Cellectar Biosciences worth $62,000 as of its most recent SEC filing. 16.41% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on Cellectar Biosciences
About Cellectar Biosciences
Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Featured Stories
- Five stocks we like better than Cellectar Biosciences
- How to Use Stock Screeners to Find Stocks
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Best Stocks Under $5.00
- 3 Must-Own Stocks to Build Wealth This Decade
- What is the Nasdaq? Complete Overview with History
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.